АДЪЮВАНТНАЯ ХИМИОТЕРАПИЯ ПРИ РАКЕ ОБОДОЧНОЙ КИШКИ


Цитировать

Полный текст

Аннотация

Рак толстой кишки занимает лидирующие позиции по заболеваемости и смертности от злокачественных опухолей. На момент постановки диагноза рак ободочной кишки I-III стадий выявляется у 67,6 % больных. Этим пациентам показано хирургическое лечение. Целью адъювантной химиотерапии (АХТ) в данной ситуации является эрадикация микрометастазов и снижение риска развития местного рецидива. Показано, что проведение послеоперационной ХТ больным раком ободочной кишки III стадии улучшает показатели безрецидивной и общей выживаемости и оно рекомендовано в качестве стандартного лечения. У пациентов со II стадией болезни проведение АХТ позволяет улучшать показатели выживаемости только в группе с факторами риска прогрессирования болезни. Решение о выборе схем и начале АХТ должно основываться на наличии у пациентов факторов риска прогрессирования болезни, эффективности и потенциальных осложнениях планируемой терапии, индивидуальных особенностях самого пациента, таких как возраст и сопутствующая патология.

Об авторах

Михаил Юрьевич Федянин

РОНЦ им. Н.Н. Блохина РАМН

РОНЦ им. Н.Н. Блохина РАМН

Алексей Александрович Трякин

РОНЦ им. Н.Н. Блохина РАМН

РОНЦ им. Н.Н. Блохина РАМН

Сергей Алексеевич Тюляндин

РОНЦ им. Н.Н. Блохина РАМН

РОНЦ им. Н.Н. Блохина РАМН

M Yu Fedyanin

A A Tryakin

S A Tyulyandin

Список литературы

  1. Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2007 г. // Вестник Российского онкологического центра им. Н.Н. Блохина РАМН 2009. Т. 20. № 3 (прил. 1).
  2. O'Connell MJ, Mailliard JA, Kahn MJ, et al. Controlled trial of fluorouracil and low dose leucovorin given 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997;15:246-50.
  3. Barone C. Adjuvant chemotherapy of colon cancer current strategies//Eur J Cancer 2008;6(Suppl):60-3.
  4. Van Cutsem E, Costa F. Progress in the adjuvant treatment of colon cancer. Has it influenced clinical practice? JAMA 2005;7:2758-60.
  5. Connell MJ. Oxaliplatin or irinotecan as adjuvant therapy for colon cancer: the results are in. J Clin Oncol 2009;27:3082-4.
  6. Biagi JJ, Raphael M, King WD, et al. The impact of time to adjuvant chemotherapy (AC) on survival in colorectal cancer (CRC): A systematic review and meta-analysis. J Clin Oncol 2011;29(4): abstr 364.
  7. Laurie JA, Moertel CG, Fleming TR, et al. Surgical adjuvant therapy of large bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil; The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol 1989;7:1447-56.
  8. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995;345:939-44.
  9. Andre T, Colin P, Louvet C, et al. Semimonthly vs monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomised trial. J Clin Oncol 2003;21:2896-903.
  10. Saini A, Norman AR, Cunningham D, et al. Twelve weeks of protracted venous infusion of fluorouracil is as effective as 6 months of bolus 5 FU and folinic acid as adjuvant treatment in colorectal cancer. Br J Cancer 2003;16:1859-65.
  11. Carrato A, Kohne C, Bedenne L, et al. Folinic acid modulated bolus 5 FU or infusional 5 FU adjuvant treatment of patients of UICC stage III colon cancer: preliminary analysis of the PETACC 2 study. Proc ASCO 2006;24:18s.
  12. Jan HM. Schellens. Cancer clinical pharmacology. Oxford Univercity Press. 2006;52.
  13. Pentheroudakis G, Twelves C. The rational development of capecitabine from the laboratory to the clinic. Anticancer Res 2002;22:3589-96.
  14. Twelves C, Wong A, Nowacki MP. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005;352:2696-704.
  15. Lembresky BC, Wieand HS, Petrelli NJ, et al. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from NSABP protocol C-06. J Clin Oncol 2006;24:2059-64.
  16. Raymond E, Buquet-Fagot C, Djelloul S, et al. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers. Anticancer Drugs 1997;8:876-85.
  17. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, 5 fluorouracil and leucovorin as adjuvant treatment of colon cancer: results of the international randomized MOSAIC trial. N Engl J Med 2004;350:2343-51.
  18. Andre T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009;27:3109-16.
  19. Kuebler JP, Wieand HS, O'Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007;25:2198-204.
  20. Haller DG, Cassidy J, Tabernero J, et al. Efficacy findings from a randomized phase III trial of capecitabine plus oxaliplatin versus bolus 5-FU/LV for stage III colon cancer (NO16968): impact of age on disease free survival. Proc ASCO 2010;20:Abst. 3521.
  21. Saltz L, Niedzwiecki D, Hollis D, et al. Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (Intergroup Trial CALGB C89903)//J Clin Oncol 2004;22:245s.
  22. Ycou M, Raoul JL, Douillard JY, et al. A phase III trial of LV5FU2+CPT11 vs LV5FU2 alone in adjuvant high risk colon cancer. Proc ASCO 2005;36:16s [abstract 3502].
  23. Van Cutsem E, Labianca R, Bodoky G, et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 2009;27:3117-25.
  24. Baluk P, Hashizume H, McDonald DM Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 2005;15:102-11
  25. Lu J, Gaudreault J, Novotny W, et al. A population pharmacokinetic model for bevacizumab. Clin Pharmacol Ther 2004;75:91.
  26. Prewett M, Huber J, Li Y, et al: Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 1999;59:5209-18.
  27. Wolmark N, Yothers G, O'Connell MJ, et al. A phase III trial comparingmFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: results of NSABPProtocol C-08. J Clin Oncol 2009;27(15):793s.
  28. de Gramont A, Van Catsem E, Tabernero J, et al. AVANT: Results from a randomized three-arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX4 versus FOLFOX4 alone as adjuvant treatment for colon cancer. J Clin Oncol 2011;29(4): abstr 358.
  29. Di Fiore F, Blanchard F, Charbonnier F, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 2007;96:1166-9.
  30. Lievre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26:374-9.
  31. Alberts SR, Sargent DJ, Smyrk TC, et al. Adjuvant mFOLFOX6 with or without Cetuximab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage II colon cancer (CC): result from NCCTG Intergroup Phase III Trial N0147. J Clin Oncol 2010;28(18):959s.
  32. Grothey A. Adjuvant chemotherapy in colon cancer - Is it worth it? Eur J Cancer 2010;46:1768-9.
  33. Quasar collaborative group. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007;370:2020-29.
  34. Koopman M, Kortman GA, Mekenkamp L, et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer 2009;100:266-73.
  35. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005;23:609-18.
  36. Jover R, Zapater P, Castells A, et al. The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. Eur J Cancer 2009;45:365-73.
  37. Bertagnolli MM, Niedzwiecki D, Compton CC, et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol 2009;27:1814-21.
  38. Roth AD, Tejpar S, Yan P, et al. Stage-specific prognostic value of molecular markers in colon cancer: Results of the translational study on the PETACC 3- EORTC 40993-SAKK 60-00 trial. J Clin Oncol 2009;27:4002.
  39. Sundararajan V, Mitra N, Jacobson JS, et al. Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann Intern Med 2002;6(5):349-57.
  40. Jessup JM, Stewart A, Greene FL, et al. Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation. JAMA 2005;294(21):2703-11.
  41. Neugut AI, Matasar M, Wang X, et al. Duration of adjuvant chemotherapy for colon cancer and survival among the elderly. J Clin Oncol 2006;24(15):2368-75.
  42. Field KM, Kosmider S, Desai J, et al. Capecitabine in colorectal cancer: a five-year review of use in routine clinical care. ASCO gastrointestinal cancers symposium; 2009.
  43. McCleary NJ, Meyerhardt J, Green E, et al. Impact of older age on the efficacy of newer adjuvant therapies in >12,500 patients (pts) with stage II/III colon cancer: findings from the ACCENT database. J Clin Oncol 2009;27(15):Abstr 4010.
  44. Allegra CJ, Yothers G, O'Connell MJ, et al. Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer.J Clin Oncol 2009;27(20):3385-90.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО «Бионика Медиа», 2011

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах